Teladoc Health stock fell 2.65 percent as revenue stayed weak
Teladoc Health (TDOC) stock declined by 2.65% to USD 5.52 on October 2, 2026, due to continued weak revenue performance. The company reported a 4% year-over-year decrease in Q2 2026 revenue to USD 606.9 million, with adjusted EBITDA of USD 65.7 million. Analysts hold a "Hold" consensus with a 12-month price target of USD 7.5357, anticipating a critical transition for its BetterHelp segment towards insurance-covered services.
Teladoc Health stock trades at EUR 5.07 before Xetra opens
Teladoc Health stock was trading at EUR 5.07 at Lang & Schwarz before Xetra opened, representing a 0.20 percent decrease from the previous close. The company announced a legal leadership change with Jonathan Dorfman becoming chief legal officer on November 2, 2026. Teladoc Health reported a revenue decline of 4.00 percent in Q2 2026 due to a drop in BetterHelp revenue, though analyst price targets remain above the current market price.
Asset turnover of Teladoc Health, Inc. – HAN:4LL
This article focuses on the asset turnover of Teladoc Health, Inc. (HAN:4LL) as listed on the Hannover Stock Exchange. It appears to be a financial data page from TradingView, providing an overview of the company's financial performance without offering detailed analysis or specific turnover figures within the provided content.
Is Teladoc Health (NYSE:TDOC) the Communication Stocks Stock Everyone's About to Talk About?
Teladoc Health (NYSE:TDOC) is gaining attention due to a specific catalyst: the announcement of a chief legal officer transition. This article emphasizes that investors should analyze this company-specific event on its own merits rather than solely relying on broader Communication Stocks sentiment. It also advises readers to monitor company filings and updates for confirmation and further details regarding this development.
Teladoc Health names Jonathan Dorfman as chief legal officer By Investing.com
Teladoc Health (NYSE:TDOC) has announced the promotion of Jonathan Dorfman to Chief Legal Officer and Secretary, effective November 2, 2026. He will succeed Adam Vandervoort, who is stepping down on November 1, 2026, after 11 years with the company. Dorfman, who joined Teladoc Health through its acquisition of Livongo in 2020, currently serves as Senior Vice President, Securities and Corporate Law.
Teladoc Health Announces Resignation of Chief Legal Officer Adam C. Vandervoort Effective November 1, 2026
Teladoc Health, Inc. (NYSE:TDOC) has announced that its Chief Legal Officer and Secretary, Adam C. Vandervoort, will resign effective November 1, 2026. Jonathan Dorfman, currently Senior Vice President, Securities and Corporate Law, will succeed him. Vandervoort will provide uncompensated advisory and transition support until November 1, 2027.
Teladoc Health (TDOC) 10K Form and Latest SEC Filings 2026
This article details Teladoc Health's (NYSE: TDOC) latest SEC filings, providing investors with access to verified financial data. It highlights the importance of 10-K, 10-Q, and 8-K reports for evaluating a company's financial health and lists recent filings including Form 8-K on September 25, 2026, and Form 4s related to insider ownership changes. The piece also explains the differences and significance of various SEC filing types.
After 11 years, Teladoc Health's legal chief will leave Nov. 1; Dorfman succeeds him Nov. 2.
Teladoc Health (NYSE: TDOC) announced that Jonathan Dorfman will succeed Adam Vandervoort as Chief Legal Officer and Secretary, effective November 2, 2026. Vandervoort is resigning on November 1, 2026, after 11 years with the company, having guided Teladoc through its IPO and the virtual care boom. Dorfman, currently Senior Vice President of Securities and Corporate Law, joined Teladoc Health in 2020 via the Livongo acquisition and has been instrumental in the company's SEC compliance and corporate governance.
Teladoc Health names Jonathan Dorfman as chief legal officer By Investing.com
Teladoc Health has announced the promotion of Jonathan Dorfman to Chief Legal Officer and Secretary, effective November 2, 2026. This appointment follows the resignation of Adam Vandervoort, who will step down on November 1, 2026, after 11 years with the company. Dorfman, who joined Teladoc through its acquisition of Livongo, has a strong background in SEC compliance and corporate governance.
Teladoc Health announces resignation of chief legal officer, names successor
Teladoc Health (NYSE:TDOC) announced the resignation of its Chief Legal Officer and Secretary, Adam C. Vandervoort, effective November 1, 2026. Jonathan Dorfman will succeed him. This leadership change comes as the telehealth company faces ongoing profitability challenges and recently reported mixed financial results for Q2 2026, including an adjusted loss and a revenue shortfall.
Teladoc Health names Jonathan Dorfman as chief legal officer
Teladoc Health, Inc. announced the promotion of Jonathan Dorfman to Chief Legal Officer and Secretary, effective November 2, 2026. This appointment follows the resignation of Adam Vandervoort, who served in the role for 11 years. Dorfman, who joined Teladoc Health through its acquisition of Livongo, has significant experience in SEC compliance, corporate governance, and capital markets.
Teladoc Health Announces Chief Legal Officer Transition
Teladoc Health, Inc. (NYSE: TDOC) has announced a leadership transition in its legal department. Adam Vandervoort, Chief Legal Officer and Secretary, is resigning effective November 1, 2026, after 11 years with the company. Jonathan Dorfman, currently Senior Vice President, Securities and Corporate Law, will succeed Vandervoort as Chief Legal Officer and Secretary, effective November 2, 2026.
Teladoc Health Announces Chief Legal Officer Transition
Teladoc Health has announced a leadership transition in its legal department. Adam Vandervoort, Chief Legal Officer and Secretary, will resign on November 1, 2026, after 11 years with the company. Jonathan Dorfman, current Senior Vice President, Securities and Corporate Law, will succeed him as Chief Legal Officer and Secretary starting November 2, 2026.
Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note
Teladoc (TDOC) shares closed down 3.46% in the latest trading session, underperforming the S&P 500's daily loss. Investors are anticipating the company's upcoming earnings report, with EPS projected to decrease by 9.52% and revenue by 6.53% compared to the same quarter last year. Despite a recent 1.78% lower revision in the Zacks Consensus EPS estimate, Teladoc currently holds a Zacks Rank of #3 (Hold).
Teladoc Health CEO Charles Divita sells $108,681 in shares
Teladoc Health CEO Charles Divita sold 17,805 shares worth $108,681 on September 11, 2026, to cover tax obligations from vested stock units. Prior to this, he acquired over 42,000 shares through unit conversions. The company's stock is currently trading at $6.35, down 24% over the past year, though InvestingPro analysis suggests it may be undervalued.
The Bull Case For Teladoc Health (TDOC) Could Change Following Weak Q2 Results And Lowered Guidance
Teladoc Health recently reported weak Q2 results, missing analyst expectations on revenue and EBITDA, and issued lower guidance for the next quarter. The company experienced a 4% year-on-year revenue decline and a 9.2% average drop in customer spending, which puts pressure on its core business model and raises concerns about its investment narrative. Despite a projected fair value offering a 27% upside, ongoing unprofitability and pricing pressures highlight the need for Teladoc to stabilize revenue per user.
Teladoc Health (TDOC) Stock Price, News & Analysis
This article provides a comprehensive overview of Teladoc Health (TDOC) stock, including its current price, news, and various analytical data points. It details the company's financial performance, analyst ratings, short interest, dividend information, and institutional ownership, offering investors a broad perspective on TDOC's market position. The content also includes a company overview, recent news headlines, and answers to frequently asked questions about the stock.
Teladoc Health | 4: Statement of changes in beneficial ownership of securities-Officer Nueno Carlos
This document is a statement of changes in beneficial ownership of securities for Teladoc Health, specifically for Officer Nueno Carlos. It details modifications in his holdings of the company's securities, as required by regulatory filings.
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
Teladoc Health, Inc. announced inducement awards for its new Chief Financial Officer, Michael Grasher, effective September 1, 2026. The awards include restricted stock units and performance stock units, tied to continued service, company adjusted EBITDA, and compound annual revenue growth. These awards were granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as per NYSE Rule 303A.08.
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
Teladoc Health announced inducement awards granted to Michael Grasher, their new Chief Financial Officer, effective September 1, 2026. The awards include restricted stock units and performance stock units tied to Teladoc Health's adjusted EBITDA for 2026 and compound annual revenue growth rate during 2026-2028. These awards were approved by the Compensation Committee and granted under NYSE Rule 303A.08.
Teladoc nabs insurance veteran as new CFO
Teladoc has appointed Michael Grasher, an insurance veteran with over three decades of experience, as its new Chief Financial Officer, effective immediately. Grasher previously served as CFO for IFG Companies and Fortegra, bringing significant public company experience and financial leadership to Teladoc. His appointment comes after Teladoc lowered its revenue guidance, partly due to challenges with its mental health services unit, and is expected to aid the company's rollout of insurance-covered services.
Teladoc appoints insurance executive Michael Grasher as CFO
Teladoc Health has appointed Michael Grasher as its new Chief Financial Officer, an industry veteran with over 30 years of experience in insurance and financial services. This appointment is viewed positively by analysts, who see it as a crucial step for Teladoc, especially given the company's recent challenges with its mental health services unit, BetterHelp, and its increasing focus on insurance-covered services. Grasher's extensive background is expected to help Teladoc navigate the growing demand for insurance-covered virtual healthcare.
Teladoc Health Appoints Michael Grasher as New CFO
Teladoc Health (TDOC) has announced the appointment of Michael Grasher as its new Chief Financial Officer, effective August 31, 2026. Grasher brings over three decades of experience in insurance and financial services, with his compensation package designed to align with disciplined growth and stakeholder value. The company's stock currently holds a Hold rating with an $8.00 price target, and TipRanks' AI Analyst views TDOC as Neutral due to improving but still unprofitable financials and weak technical momentum.
Teladoc Health names Michael Grasher as chief financial officer
Teladoc Health, Inc. has announced the immediate appointment of Michael Grasher as its new Chief Financial Officer. Grasher brings over 30 years of experience in the insurance and financial services sectors, including more than 12 years in CFO roles at both public and private companies. His previous positions include CFO roles at IFG Companies, Fortegra, and AMERISAFE, as well as a decade in equity research.
Teladoc Health Appoints Michael Grasher as Chief Financial Officer
Teladoc Health has appointed Michael Grasher as its new Chief Financial Officer, effective immediately. Grasher brings over three decades of financial experience across insurance and financial services, including more than 12 years in CFO roles for public and private companies. His appointment is expected to strengthen Teladoc Health's financial leadership as it focuses on strategic execution and long-term growth.
Teladoc Health Appoints Michael Grasher as Chief Financial Officer
Teladoc Health has announced the appointment of Michael Grasher as its new Chief Financial Officer, effective immediately. Grasher brings over three decades of financial experience, including CFO roles at public and private companies in the insurance and financial services sectors. His expertise is expected to help Teladoc Health strengthen its business, execute strategic priorities, and deliver long-term value.
Teladoc Health (TDOC) Is Down 6.2% After Cutting 2026 Outlook And BetterHelp Strains - Has The Bull Case Changed?
Teladoc Health (TDOC) recently cut its full-year 2026 revenue guidance due to pressures on its BetterHelp platform and is facing a securities-law investigation. This news has led to a 6.2% drop in its stock and raises questions about the company's evolving business model, particularly as BetterHelp shifts to an insurance-based model from cash pay. Despite the challenges, Teladoc's narrative projects future revenue and earnings growth, suggesting a potential 25% upside to its current price according to some analyses.
Teladoc Health (TDOC) Is Down 6.2% After Cutting 2026 Outlook And BetterHelp Strains - Has The Bull Case Changed?
Teladoc Health's stock (TDOC) is down 6.2% after the company cut its 2026 revenue guidance, citing pressures on its BetterHelp platform and facing a securities-law investigation. The reduced outlook and challenges to BetterHelp's cash pay model raise questions about the company's investment narrative, particularly concerning the stabilization of growth and margins as it transitions to insurance-based services. Investors are urged to consider these new developments, especially given that even the most bearish analysts had already anticipated revenue shrinkage and reimbursement risks.
Is Teladoc Health (TDOC) Cheap As Board Changes Stir Fresh Valuation Questions?
Teladoc Health (TDOC) is facing valuation questions as a director announces retirement and the stock has seen significant declines over various periods. Despite this, the company generated strong free cash flow in 2025, is guided for similar results in 2026, and holds substantial cash reserves. While a fair value of $15.00 is proposed, risks like margin pressure from BetterHelp insurance changes and competition remain.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC
Pomerantz LLP is investigating potential securities fraud claims against Teladoc Health, Inc. (NYSE: TDOC) on behalf of its investors. This investigation follows Teladoc's updated 2026 revenue guidance, which was significantly lowered due to "uncertainties inherent in cash pay and ongoing business model transition," and pressures on its BetterHelp platform. Following this announcement, Teladoc's stock price dropped by 38.32%.
Did Teladoc Health, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Teladoc Health, Inc. (NYSE: TDOC) breached their fiduciary duties to shareholders. The firm urges current long-term Teladoc shareholders to contact them to explore options for corporate governance reforms, return of funds, or other relief. Shareholder involvement is highlighted as a way to improve company transparency and accountability.
Law firm probes Teladoc Health officers for possible shareholder rights breaches
Halper Sadeh LLC is investigating Teladoc Health (TDOC) officers and directors for potential breaches of fiduciary duties to shareholders, offering to handle claims on a contingent fee basis. This follows a previous securities fraud probe by Pomerantz LLP after Teladoc cut its 2026 revenue forecast, causing its stock to plunge. The law firm aims to improve corporate governance and recover funds for affected investors.
Teladoc Health (TDOC) Could Be 55% Undervalued On Board Change And 2026 Guidance
Teladoc Health (TDOC) is considered 55% undervalued by Simply Wall St, with a fair value of $15.00 against its current price of $6.81. This assessment follows the appointment of Mark V. Anquillare to its board and updated 2026 guidance, highlighting the company's cash generation, insurance-driven mental health model, and shift away from being solely a pandemic beneficiary. Despite recent share price pressure, the analysis suggests Teladoc's underlying financials are strong.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Teladoc Health, Inc. (TDOC) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teladoc Health, Inc. (TDOC) following a significant drop in its stock price. The investigation stems from Teladoc's second-quarter 2026 financial results, which missed analyst expectations, and its subsequent downward revision of full-year revenue guidance, particularly due to accelerated declines in cash pay users for its BetterHelp platform. Shareholders are encouraged to contact the firm to assist in the investigation.
Teladoc Health | 4: Statement of changes in beneficial ownership of securities-Officer Catapano Joseph Ronald
This document is a Statement of Changes in Beneficial Ownership of Securities, specifically Form 4, filed by Joseph Ronald Catapano, an officer at Teladoc Health. This filing indicates a change in his beneficial ownership of securities in the company.
Teladoc Health (TDOC) Could Be 55% Undervalued On Board Change And 2026 Guidance
Teladoc Health (TDOC) is considered 55% undervalued at its current share price of $6.81, with a fair value estimated at $15.00, according to Simply Wall St's analysis. This assessment follows the appointment of Mark V. Anquillare to its board and updated 2026 guidance. The company is highlighted as a cash-generative healthcare utility with significant cash reserves and a growing insurance-reimbursed mental health model, despite recent share price pressure.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Teladoc Health, Inc. (TDOC) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teladoc Health, Inc. (TDOC) following the company's Q2 2026 financial results, which reported lower-than-expected revenue and a reduced full-year guidance. The investigation focuses on potential claims for purchasers of Teladoc Health securities, especially after the stock price dropped significantly due to an accelerated decline in cash pay users and slower-than-expected insurance capacity expansion for its BetterHelp service. Investors are encouraged to seek more information about the investigation.
Teladoc Health (TDOC) Is Up 6.7% After Faster BetterHelp Insurance Shift Tightens 2026 Outlook
Teladoc Health's stock rose 6.7% following the acceleration of BetterHelp's nationwide insurance rollout, prompted by higher-than-expected insured demand. This shift, however, reduced the overall BetterHelp revenue outlook due to provider capacity constraints and a quicker move away from cash-pay users. The company's updated guidance for 2026 forecasts revenue between US$2.36 billion and US$2.45 billion, with a net loss of US$181 million to US$136 million, reflecting the ongoing challenge of balancing growth with profitability in the virtual care market.
Teladoc Health, Inc. (TDOC) Stock Analysis: Exploring a 16% Upside Potential Amidst Revenue Challenges
Teladoc Health (TDOC) is a leading virtual healthcare provider facing financial challenges despite its innovative role in the sector. The company has a market capitalization of $1.21 billion, with recent revenue decline and negative EPS, yet it maintains a healthy free cash flow. Analysts are cautiously optimistic, with an average target price suggesting a 16.21% upside, presenting a complex risk-reward profile for investors.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Teladoc Health, Inc. (TDOC) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Teladoc Health, Inc. (NYSE: TDOC) investors. This investigation follows Teladoc's report of second-quarter 2026 financial results, which showed lower-than-expected revenue and a reduced full-year guidance, largely due to an accelerated decline in cash pay users for BetterHelp and slower-than-anticipated expansion of insurance capacity. The news led to a significant drop in Teladoc's stock price, prompting the firm to encourage affected investors to participate in their investigation.
Teladoc Health Inc (TDOC) Stock News Today
This article provides the current stock information for Teladoc Health Inc (TDOC), including its trading price, daily change, market capitalization, and a note that more news will be available soon. It highlights that the stock closed at 7.130 USD, up 6.74%, with a market cap of 1.29B. The page serves as a hub for news, analysis, and financial data for TDOC.
Teladoc Health (TDOC) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky has announced a securities investigation into Teladoc Health (TDOC) after its shares dropped over 28%. This plunge followed Teladoc's report of Q2 2026 revenue below consensus and a cut in its full-year 2026 revenue guidance. The investigation focuses on potential materially false or misleading statements regarding the company's financial outlook.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC
Pomerantz LLP is investigating potential claims on behalf of investors of Teladoc Health, Inc. (NYSE: TDOC) concerning alleged securities fraud or unlawful business practices. This investigation follows Teladoc's updated 2026 revenue guidance, which was significantly lowered due to "uncertainties inherent in cash pay and ongoing business model transition," causing a 38.32% drop in the company's stock price on July 30, 2026. Investors are encouraged to contact Pomerantz LLP for more information.
Bronstein, Gewirtz & Grossman, LLC Encourages Teladoc Health, Inc. (TDOC) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating Teladoc Health, Inc. (TDOC) on behalf of investors following a significant drop in its stock price. This drop occurred after Teladoc reported lower-than-expected Q2 2026 revenue and subsequently reduced its full-year 2026 revenue guidance. The firm cites an acceleration in the decline of cash pay users and slower-than-anticipated expansion in insurance capacity for Teladoc's BetterHelp service as key factors contributing to the financial shortfall.
Securities Fraud Investigation Into Teladoc Health Inc. (TDOC) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz has initiated a securities fraud investigation into Teladoc Health Inc. (TDOC) following a significant drop in its stock price. This investigation comes after Teladoc reduced its full-year revenue guidance and reported a more drastic reduction in BetterHelp's segment performance due to increased consumer movement towards insurance, provider capacity constraints, and a decline in cash pay users. Shareholders who lost money are encouraged to contact the firm to potentially pursue a claim.
Dimensional Fund Advisors LP Decreases Stake in Teladoc Health, Inc. $TDOC
Dimensional Fund Advisors LP significantly reduced its stake in Teladoc Health, Inc. by 16% in the first quarter, selling 1.2 million shares but still retaining over 6.3 million shares valued at approximately $34.3 million. Despite beating EPS estimates, Teladoc's revenue declined year-over-year and missed expectations. The company currently holds a consensus "Hold" rating from analysts, with a mixed outlook on price targets.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Teladoc Health, Inc. (TDOC) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teladoc Health, Inc. (TDOC) following the company's Q2 2026 financial results, which reported lower-than-expected revenue and a reduced full-year guidance. The investigation focuses on potential claims for investors who purchased Teladoc Health securities, especially after the stock price dropped significantly due to an accelerated decline in BetterHelp cash pay users and slower-than-anticipated insurance expansion. Investors are encouraged to contact the firm for more information.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Teladoc Health (TDOC)
Levi & Korsinsky is investigating Teladoc Health (NYSE: TDOC) on behalf of investors who lost money after the company reported lower-than-expected Q2 2026 revenue and cut its full-year guidance. Teladoc's stock fell almost 30% in a single session following the announcement of $606.9 million in revenue against consensus estimates of $615 million to $628 million, and a significant reduction in its full-year 2026 revenue outlook. Investors who purchased TDOC shares and suffered losses are encouraged to contact the firm for a no-cost review of their recovery options.
Teladoc Health (NYSE: TDOC) director Mark Anquillare submits initial Form 3
Teladoc Health Inc. (NYSE: TDOC) director Mark V. Anquillare has filed an initial Form 3, indicating his beneficial ownership of securities as a director. The filing reports no equity transactions and includes a reference to a Power of Attorney. This Form 3 establishes Anquillare's disclosure obligations for any future transactions in TDOC securities.
Teladoc Health | 4: Statement of changes in beneficial ownership of securities-Director Anquillare Mark V
This article reports a change in the beneficial ownership of securities for Mark V. Anquillare, a Director at Teladoc Health. The filing is a Statement of Changes in Beneficial Ownership, also known as a Form 4. This indicates that there has been a transaction involving Anquillare's holdings in the company.
